Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $65.57.

Several brokerages have recently commented on JANX. Wedbush restated an "outperform" rating and set a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. HC Wainwright raised their price objective on shares of Janux Therapeutics from $50.00 to $63.00 and gave the company a "buy" rating in a research report on Monday, May 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, Scotiabank decreased their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating on the stock in a research note on Friday, August 9th.

Insider Activity at Janux Therapeutics

In other news, CFO Tighe Reardon sold 822,721 shares of the firm's stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the transaction, the chief financial officer now directly owns 633,673 shares in the company, valued at approximately $34,693,596.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Jay Lichter sold 1,500,000 shares of the business's stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $82,125,000.00. Following the completion of the transaction, the director now owns 633,673 shares in the company, valued at $34,693,596.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Tighe Reardon sold 822,721 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $45,043,974.75. Following the completion of the sale, the chief financial officer now owns 633,673 shares in the company, valued at $34,693,596.75. The disclosure for this sale can be found here. Insiders have sold 3,000,000 shares of company stock worth $164,250,000 over the last ninety days. Company insiders own 35.40% of the company's stock.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank grew its stake in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company's stock valued at $41,000 after acquiring an additional 368 shares during the period. Summit Securities Group LLC bought a new position in shares of Janux Therapeutics during the 2nd quarter valued at about $29,000. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics in the 2nd quarter valued at approximately $42,000. Nisa Investment Advisors LLC increased its stake in Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company's stock worth $29,000 after purchasing an additional 2,685 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Janux Therapeutics during the 2nd quarter worth approximately $151,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

Shares of JANX traded down $0.20 during mid-day trading on Friday, hitting $41.32. The company's stock had a trading volume of 321,491 shares, compared to its average volume of 756,332. Janux Therapeutics has a one year low of $5.65 and a one year high of $65.60. The stock's 50-day moving average is $41.17 and its two-hundred day moving average is $39.78. The firm has a market capitalization of $2.14 billion, a PE ratio of -33.87 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The business's revenue for the quarter was up 709.1% compared to the same quarter last year. Analysts expect that Janux Therapeutics will post -1.34 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.